07:04 AM EDT, 10/23/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) company Janssen-Cilag International said Wednesday that the European Commission (EC) has approved an indication extension for its subcutaneous Darzalex formulation in combination with bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.

The drug, also known as daratumumab, was approved for the expanded indication after a 709-patient late-stage study showed the potential to improve progression-free survival and response rates when compared with the current standard of care.

Daratumumab has been approved for use in treating multiple myeloma, an incurable blood cancer, since 2016, the company said.

Price: 163.78, Change: +0.33, Percent Change: +0.20